Pfizer to pay $43B for Seagen, boosting cancer drug portfolio
The latest deal comes as Pfizer seeks to mitigate an anticipated $17 billion hit to revenue by 2030 from patent expirations for top drugs and decline in demand for its COVID products.
Top tags
Today most read articles
Article
Similar articles